American Society for Radiation Oncology

Veracyte Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Radiation therapy, IVD, GAAP, Acquisition, Prostate cancer, JCO, Society, Prostate, Growth, Webcast, Abstract, American Society for Radiation Oncology, Cancer, ASTRO, Table, Patient, GM, GRID, Pharmaceutical industry, Video game, Medical imaging, Illumina

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023.
  • Total revenue for the third quarter of 2023 was $90.1 million, an increase of 19% compared to $75.6 million reported in the third quarter of 2022.
  • Total gross margin for the third quarter of 2023, including the amortization of acquired intangible assets, was 64%, compared to 59% in the third quarter of 2022.
  • Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update.

LUNGevity Foundation Announces $1.2M in Lung Cancer Workforce Development Research Awards

Retrieved on: 
Wednesday, November 1, 2023
Neoplasm, Radiation, Faculty, Research, NSCLC, Health equity, RNA, ICI, Doctor of Philosophy, Cell, METTL3, Disease, Partnership, Radiation therapy, SCLC, MPH, LCI, Health, Lung cancer, Physician, Workforce, Veteran, Maintenance, Immune system, KIR, Breast cancer, Immunotherapy, Checkpoint, Cancer, Patient, Laboratory, ICIS, Durham, MD, Growth, Development, American Society for Radiation Oncology, LSD1, ASTRO, Survival, FDA, MBA, Treatment of lung cancer, Society, Death, Genomics, Risk, Carcinoma, Diagnosis, LCS, Nursing, Medical imaging, Vaccine

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to continue its multifaceted investment in the thoracic oncology workforce by announcing the recipients of four awards — the Career Development Award, the VA Research Scholar Award, the Health Equity and Inclusiveness Research Fellow Award, and the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant. 

Key Points: 
  • "Progress in lung cancer research is only possible with a vibrant and diverse thoracic oncology workforce," notes Upal Basu Roy, PhD, MPH, executive director, LUNGevity Research.
  • LUNGevity Foundation is honored to partner with the Lung Cancer Initiative (LCI) to co-fund Dr. LoPiccolo's project on the genomics of young-onset lung cancer.
  • The Lung Cancer Initiative is a leading nonprofit in North Carolina that connects the lung cancer community with the research and medical community.
  • LUNGevity's 2023 VA Research Scholar Award recipient is:
    Lung cancer screening (LCS) provides an important opportunity to find lung cancer early when it is the most treatable.

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

Retrieved on: 
Wednesday, October 4, 2023
Health, Genetics, Radiology, Clinical Trials, Oncology, Docetaxel, NRG, Prostate-specific antigen, Radiation, University, DM, ASTRO, MFS, Clinical trial, University Hospitals Cleveland Medical Center, ADT, Research, Risk, Prostate, Gene expression, Radiation therapy, Maryland School, University of Maryland School of Medicine, Patient, Physician, Annual general meeting, Case Western Reserve University School of Medicine, Urology, Society, PSA, American Society for Radiation Oncology, Biopsy, Prostate cancer, Medical imaging

(Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer.
  • Data from a second study presented at ASTRO 2023 reveal there is minimal to moderate risk-score correlation between the gene expression signatures of three commercially available genomic classifiers, including the Decipher Prostate test.
  • Researchers generated Decipher Prostate test scores using biopsy samples from 183 patients, who were followed for a median of 9.9 years.
  • Additionally, patients with higher-risk Decipher Prostate genomic scores had worse DM (sHR 2.82, 95% CI) compared to those with lower-risk scores.

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Genetics, Radiology, Pharmaceutical, Biotechnology, SCC, Medical University of South Carolina, T2A, Head, ASTRO, MFS, ART, Medical school, Radiation therapy, Patient, Risk, Annual general meeting, American Society for Radiation Oncology, BWH, Society, Metastasis, Medical imaging, Brigham

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART).
  • The data will be shared in an oral presentation during the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting, being held Oct. 1-4 in San Diego.
  • “When a patient’s risk of metastasis is unclear, tough decisions as to which treatment approaches to pursue become that much more difficult.
  • An intermediate risk population in which ART is often considered was defined as Brigham and Women’s Hospital (BWH) stage T2a or higher (n=489).

GT Medical Technologies, Inc. Presents New Data Further Demonstrating High Local Control for the Treatment of Recurrent Brain Metastases at the ASTRO 2023 Annual Meeting

Retrieved on: 
Monday, October 2, 2023
San Diego Convention Center, Brain, Radiation, Q&A, American Society for Radiation Oncology, ASTRO, Booth, Radiation therapy, Barrow Neurological Institute, Incidence, Publication, MD, Patient, Baptist Health, Annual general meeting, Poster, FDA, Society, Safety, Medical imaging, Medical device, Brachytherapy, Radiosurgery

TEMPE, Ariz., Oct. 2, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced interim findings of a multi-institutional study that demonstrates high local control for the treatment of recurrent brain metastases in patients, adding to the growing evidence of the efficacy and safety of its FDA-approved GammaTile® Therapy at the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting.

Key Points: 
  • None of the patients experienced adverse effects from the radiation treatment in follow-ups, which had a median time of four months post-surgery.
  • "This robust emerging scientific data reinforces the impact GammaTile Therapy has on local control for patients with brain metastases.
  • The poster, titled: "Surgically Targeted Radiation Therapy (STaRT) for Brain Metastases: Initial Experience from a Prospective Multi-institutional Registry" will be available on the ASTRO Annual Meeting Portal .
  • The results showed that GammaTile for operable recurrent brain metastases was associated with superior local control compared to the first course of external beam radiotherapy in the series.

Image-Guided Superficial Radiation Therapy Yields Superior 2-Year Recurrence Rates Compared to Mohs Micrographic Surgery, Cancer Journal Reports

Retrieved on: 
Monday, October 2, 2023
Columbia University, Contraindication, Columbia University Irving Medical Center, Cleveland Clinic, SCC, Radiation, Probability, University, Coagulopathy, Doctor of Philosophy, Skin, Anatomy, ASTRO, Mohs surgery, SRT, Skin cancer, Cancer, NMSC, MMS, BCC, Head, National Comprehensive Cancer Network, Toxicity, Research, Radiation therapy, Neck, SCCS, Medical Subject Headings, Dermatology, Incidence, Death, Patient, Treatment, University of South Florida College of Medicine, Carcinoma, American Society for Radiation Oncology, PubMed, European Society for Medical Oncology, Recurrence, Society, Medical imaging, Veterinary medicine, Dentistry, Pharmaceutical industry, Physician, Surgeon

BURR RIDGE, Ill., Oct. 2, 2023 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT, or IGSRT), today announced a newly published study revealing that IGSRT technology is superior to Mohs micrographic surgery (MMS). Image-Guided SRT is the most advanced nonsurgical treatment for common skin cancers. This peer-reviewed study "supports IGSRT as an effective treatment option for individuals with early stage NMSCs (nonmelanoma skin cancers)." The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.

Key Points: 
  • The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.
  • The report, entitled, "Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgery," appears in the journal Clinical and Translational Radiation Oncology , which is published by the European Society for Radiotherapy & Oncology (ESTRO).
  • Medical Subject Headings were used to search PubMed for reports of 2-year recurrence probability rates of NMSCs treated by MMS.
  • The authors observe that prior to the invention of Mohs surgery, superficial radiation therapy (SRT) was a standard therapy offered by dermatologists for nonmelanoma skin cancer.

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Retrieved on: 
Monday, October 2, 2023
Vaccine, DNA, Biotechnology, University, FIGO, Nucleic acid thermodynamics, PDSB, Neoplasm, ASTRO, Infection, HPV16, Cancer, SOC, Monroe Dunaway Anderson, Radiation therapy, Doctor of Philosophy, MD Anderson Cancer Center, CD8, Cervical cancer, MD, Patient, Lymph, Blood, Annual general meeting, American Society for Radiation Oncology, HPV, Chemoradiotherapy, Gynaecology, Oncology, CRT, Kinetics, Society, Human papillomavirus infection, Disease, Birth control, Medical imaging, Obstetrics

HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.

Key Points: 
  • HPV is the primary cause of cervical cancer with over 99% caused by HPV infection, and cfHPV-DNA can be detected in the blood of patients with cervical cancer.
  • HPV type 16 (HPV16) is the most prominent subtype associated with cervical cancer.
  • Longitudinal plasma samples were collected from each patient at baseline, during weeks 1, 3, and 5, and at 3-4 months after CRT.
  • “I look forward to the continued evaluation of PDS0101 in combination with standard-of-care chemoradiotherapy.”

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Monday, October 2, 2023
SBRT, Cyberknife, SRS, CE, Radiation, Partnership, DIBH, Workflow, Alliance University (New York City), Neoplasm, ASTRO, Cancer, Radiation therapy, Sale, Limbus, Patient, Risk, Annual general meeting, Physics, Society, American Society for Radiation Oncology, Software, Medical device, Medical imaging, EU, Accuray, Ceno

The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.

Key Points: 
  • The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.
  • Accuray customers are currently able to leverage real-time adaptive therapy through the company's proprietary Synchrony® technology and offline adaptive with PreciseART® radiotherapy to account for some of the anatomical changes that occur during radiation delivery.
  • "We're very happy to be partnering with Accuray," said Dr Karl Otto, CEO of Limbus AI.
  • Embedding it into the Cenos online adaptive solution will help provide for accurate and fast contouring essential to real-world clinical implementation of adaptive treatment."

PreludeDx™ Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT®

Retrieved on: 
Monday, October 2, 2023
San Diego Convention Center, Surgeon, Impact, ASTRO, MSKCC, Woman, Virtual, Radiation therapy, Ductal carcinoma, IBR, NPV, Patient, Physician, Risk, Medicine, Annual general meeting, DCIS, RT, BCS, Society, American Society for Radiation Oncology, Medical imaging, MD

These DCISionRT High-Risk patients had high 10-year ipsilateral breast recurrence (IBR) rates and significant radiation therapy (RT) benefit.

Key Points: 
  • These DCISionRT High-Risk patients had high 10-year ipsilateral breast recurrence (IBR) rates and significant radiation therapy (RT) benefit.
  • In contrast, the corresponding DCISionRT Low-Risk patients had low 10-yr IBR rates and no significant RT benefit.
  • “Prior to DCISionRT, we relied primarily on traditional clinicopathologic factors to make treatment decisions.
  • Conversely, the study also demonstrated patients reclassified into the DCISionRT High-Risk groups had higher IBR rates without RT (20% and 12%) and significant absolute IBR rate reductions (13% and 8%) from RT.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Unveil Wide Range of Innovative Radiation Oncology Research at the 2023 ASTRO Annual Meeting

Retrieved on: 
Friday, September 29, 2023
KRAS, Abstract, RWJBarnabas Health, ASTRO, Survival, NCI-designated Cancer Center, Cancer, National Cancer Institute, Radiation, Breast, Research, Radiation therapy, Lung cancer, Immunotherapy, Associate, Lung, MS, PDA, MRD, Cooper University Hospital, Patient, Standard of care, Annual general meeting, Chemoradiotherapy, Rutgers Cancer Institute of New Jersey, Radio, Society, American Society for Radiation Oncology, Methionine, Medical imaging, MD

NEW BRUNSWICK, N.J., Sept. 29, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present new, novel, and expansive radiation oncology data from their clinical research program at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held in San Diego from October 1-4.  A total of 10 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and use of radiation therapy in the treatment of lung, breast, pancreatic, and other cancers. Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute and RWJBarnabas Health is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "We are excited that the physician-scientists from our health system will be presenting significant and valuable information to advance the use of radiotherapy in cancer treatment at this year's ASTRO meeting," said Bruce Haffty, MD, MS, Chair, Radiation Oncology, Associate Vice Chancellor for Cancer Programs at Rutgers Cancer Institute of New Jersey, and System Director of Radiation Oncology at RWJBarnabas Health.
  • Highlights of accepted abstracts include the following:
    Findings of an analysis to explore genetic changes in aggressive pancreatic cancer.
  • The full list of presentations at this year's ASTRO Annual Meeting follows: